Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study (Q57168139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

patient

0 references

hepatocellular carcinoma

1 reference

Markus Peck-Radosavljevic

inferred from title

author

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Wolfgang Sieghart

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Matthias Pinter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Michael Reisegger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Christian Müller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ahmed Ba-Ssalamah

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Johannes Lammer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

4 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

1214-1223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00330-011-2368-z

19 January 2020

exact match

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2368-Z

Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma.

21 January 2018

1 reference

12 December 2020

Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center

1 reference

12 December 2020

Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S00330-011-2368-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22215073%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference